Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Nature Communications|June 21, 2020
MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosisAndre L Samson, Ying Zhang, Niall D Geoghegan, et al.Blood Advances|June 23, 2020
Cotargeting BCL-2 and MCL-1 in high-risk B-ALLDonia M Moujalled, Diane T Hanna, Soroor Hediyeh-Zadeh, et al.Frontiers in Chemistry|May 2, 2022
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro InhibitorsDale J Calleja, Nathan Kuchel, Bernadine G C Lu, et al.Blood Advances|June 8, 2021
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropeniaEmma M Carrington, Cynthia Louis, Tobias Kratina, et al.Science (New York, N.Y.)|February 24, 2018
BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosisKate McArthur, Lachlan W Whitehead, John M Heddleston, et al.Nature Communications|March 18, 2015
A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine productionUeli Nachbur, Che A Stafford, Aleksandra Bankovacki, et al.ACS Medicinal Chemistry Letters|June 20, 2014
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XLMichael F T Koehler, Philippe Bergeron, Edna F Choo, et al.The EMBO Journal|August 27, 2020
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2Theresa Klemm, Gregor Ebert, Dale J Calleja, et al.Cell Death & Disease|March 13, 2021
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumorsChristoph Grohmann, Francesca Walker, Mark Devlin, et al.Nature Chemical Biology|October 9, 2019
A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosisMark F van Delft, Stephane Chappaz, Yelena Khakham, et al.Pageof 9